Submitted by Office of Gov. Mike Braun
On Thursday, July 30, Governor Mike Braun directed the Indiana Family and Social Services Administration (FSSA) to participate in the Center for Medicare and Medicaid Innovation’s BALANCE demonstration, expanding access to select GLP-1 medications for eligible Indiana Medicaid members living with obesity.
Under the terms of the demonstration, pharmaceutical manufacturers, including Indiana’s own Eli Lilly and Company and Novo Nordisk, will make select GLP-1 medications available to Indiana’s Medicaid program for $245 per member per month. After accounting for the Federal government’s contribution, Indiana will pay just $85.16 per person per month. The agreement increases access to obesity treatment for eligible Medicaid beneficiaries, providing Hoosiers and their healthcare providers with effective treatment options while giving the state a predictable pricing structure. Manufacturers will also provide a lifestyle support program at no additional cost to the state.
“Indiana is proud to expand access to essential treatment for eligible Hoosiers,” Gov. Braun said. “This agreement reflects our commitment to Make Indiana Healthy Again by pursuing practical solutions that increase healthier lives.”
Increasing access to obesity treatment has the potential to help more Hoosiers remain in the workforce, return to work, and reduce reliance on public assistance programs. Additional implementation details, including eligibility criteria and timing, will be announced as the agreement is finalized.
Be the first to comment on "Medicaid will now cover GLP-1 treatments for eligible beneficiaries"